EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSODEG00000011392
Gene Symbol: PSMD12
2 Cross references
217 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSODEG00000015037
Gene Symbol: PSMD13
3 Cross references
218 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSODEG00000015872
Gene Symbol: PSMD14
3 Cross references
211 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 4

Ensembl ID : ENSODEG00000011837
Gene Symbol: PSMD4
2 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSODEG00000003221
Gene Symbol: PSMD6
1 Cross references
213 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSODEG00000015308
Gene Symbol: PSMD7
2 Cross references
237 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSODEG00000015452
Gene Symbol: PSMD8
3 Cross references
178 Possible Orthologues:

Proteasome Subunit Alpha Type-1-Like

Ensembl ID : ENSODEG00000002721
Gene Symbol: LOC101564803
2 Cross references
251 Possible Orthologues:

Proteasome Subunit Alpha Type-3-Like

Ensembl ID : ENSODEG00000004389
Gene Symbol: LOC101568672
2 Cross references
216 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSODEG00000018719
Gene Symbol: PSMB11
3 Cross references
227 Possible Orthologues:

Proteasome Subunit Beta Type-3

Ensembl ID : ENSODEG00000019417
Gene Symbol: LOC101571396
2 Cross references
257 Possible Orthologues:

Proteasome Subunit Beta Type-6

Ensembl ID : ENSODEG00000012916
Gene Symbol: LOC105742784
2 Cross references
211 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).